Overview

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Status:
Not yet recruiting

Trial end date:
2028-12-01

Target enrollment:

Participant gender:

Summary

This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free survival（rPFS） based on BICR assessment

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Abiraterone Acetate
Prednisone